ArticleJournal of medicinal chemistry2026
Structure-Activity Relationships of Silver(I)- and Gold(I)-NHC Complexes Reveal Distinctly Different Responses of Cisplatin-Resistant Ovarian Cancer to Bis-NHC-Gold(I) Derivatives.
Julia H Bormio Nunes, Christina Hacker, Monika Caban, Daniel Valcanover, Patrick A Yassemipour, Sebastian Türck, Ingo Ott, Lukas Skos, Andrea Bileck, Christopher Gerner and 5 more
Abstract read
In one paragraphArticle in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Julia H Bormio NunesInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.ORCID 0000-0001-8113-6679 Christina HackerCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria.
Monika CabanCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria.
Daniel ValcanoverCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria.
Patrick A YassemipourInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
Sebastian TürckInstitute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Braunschweig 38106, Germany.
Ingo OttInstitute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Braunschweig 38106, Germany.
Lukas SkosDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.ORCID 0000-0003-3983-1736 Andrea BileckDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.ORCID 0000-0002-7053-8856 Christopher GernerDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.ORCID 0000-0003-4964-0642 Samuel M Meier-MenchesInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.ORCID 0000-0002-8930-4574 Thomas MohrCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria.
Walter BergerCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0003-0014-1658 Christian R KowolInstitute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.ORCID 0000-0002-8311-1632 Petra HeffeterCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0001-6401-8646 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Ovarian cancer (OC) is the most lethal gynecological malignancy, with platinum resistance posing a major therapeutic challenge. To explore alternatives, we synthesized silver- and gold-based
Indexed as
Antineoplastic AgentsCisplatinCoordination ComplexesDrug Resistance, NeoplasmGoldMethaneOvarian NeoplasmsSilverApoptosisCell Line, TumorFemaleHumansStructure-Activity RelationshipAntineoplastic AgentscarbeneCisplatinCoordination ComplexesGoldMethaneSilver
Identifiers
PMID41592004
PMCPMC12910662
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390